Form 4 for PCVX Vaxcyte, Inc.
Accepted 2021-07-28 00:00:00 ET · period of report 2021-07-26 · accession 0001209191-21-048429 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-28 | 2021-07-26 | PCVX | Fairman Jeff | VP, Research | S - Sale+OE | $22.70 | -4,750 | 5,144 | -48% | -$107.8K |
| D | 2021-07-28 | 2021-07-26 | PCVX | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,750 | 9,894 | +92% | +$8,502 |
| D | 2021-07-28 | 2021-07-26 | PCVX | Fairman Jeff | VP, Research | M - OptEx | $0.00 | -4,750 | 77.1K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-26 | S | D | 4,750 | $22.70 | 5,144 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $22.50 to $22.935. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2021-07-26 | M | A | 4,750 | $1.79 | 9,894 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2021-07-26 | M | D | 4,750 | $0.00 | 77,095 | D | $1.79 · — to 2027-05-17 | 4,750 Common Stock | (F3) The shares subject to the option are fully vested and exercisable. |